We use cookies to understand how you use our site and to improve your experience.
This includes personalizing content and advertising.
By pressing "Accept All" or closing out of this banner, you consent to the use of all cookies and similar technologies and the sharing of information they collect with third parties.
You can reject marketing cookies by pressing "Deny Optional," but we still use essential, performance, and functional cookies.
In addition, whether you "Accept All," Deny Optional," click the X or otherwise continue to use the site, you accept our Privacy Policy and Terms of Service, revised from time to time.
You are being directed to ZacksTrade, a division of LBMZ Securities and licensed broker-dealer. ZacksTrade and Zacks.com are separate companies. The web link between the two companies is not a solicitation or offer to invest in a particular security or type of security. ZacksTrade does not endorse or adopt any particular investment strategy, any analyst opinion/rating/report or any approach to evaluating individual securities.
If you wish to go to ZacksTrade, click OK. If you do not, click Cancel.
Here's Why You Should Add Solventum Stock to Your Portfolio Now
Read MoreHide Full Article
Key Takeaways
SOLV posted strong Q4 results, with earnings and sales beating estimates across key business segments.
Solventum targets $500M in savings from its restructuring plan, with gains starting in 2026.
SOLV faces tariff pressures and potential 3M-related raw material cost increases impacting margins.
Solventum Corporation (SOLV - Free Report) is well-poised for growth in the coming quarters, driven by strong demand across its business segments, supported by continued investment in innovation, R&D and digital capabilities. The optimism, led by a solid fourth-quarter 2025 performance and a solid restructuring program, is expected to contribute further. However, concerns regarding a rise in raw material costs persist.
In the year-to-date period, this Zacks Rank #2 (Buy) company’s shares have lost 11.6% compared with the industry’s 8.9% decline and the S&P 500’s 4.3% rise.
The renowned global healthcare solutions provider has a market capitalization of $12.2 billion. The company projects 4.3% earnings growth for 2026 and expects to maintain its strong performance going forward. Solventum’s earnings surpassed the Zacks Consensus Estimate in each of the trailing four quarters, the average surprise being 12.4%.
Let’s delve deeper.
Image Source: Zacks Investment Research
Key Drivers of SOLV Stock
Future Cost Transformation Program: Solventum introduced its multi-year “Transform for the Future” restructuring program, targeting approximately $500 million in cost savings through operational efficiencies, system streamlining and automation, with benefits starting in 2026 and the majority realized from 2027 onward to support margin expansion and reinvestment. This builds on the successful completion of the Solventum Way program in 2025, which created a more flexible operating structure and delivered $125 million in annualized savings at a lower-than-expected cost, further strengthening the company’s ability to fund growth initiatives.
Strategic Growth Drivers: Solventum identified five core growth drivers that are expected to account for more than 80% of its future expansion, centered on segments where it already holds strong brand equity and clinical differentiation. Within MedSurg, negative pressure wound therapy continues to represent a sizable opportunity, fueled by growing adoption of Prevena and the V.A.C. Peel and Place dressing, while IV site management is gaining traction on the back of increasing demand for Tegaderm CHG and ample room for further market penetration.
The company is also seeing steady progress in sterilization assurance, supported by recent Attest product introductions. Beyond MedSurg, innovation remains a key pillar, with roughly 20 new product launches planned over the next two years. In Dental, growth is being driven by core restorative offerings such as Clinpro Clear and Filtek Easy Match, while in Health Information Systems, revenue cycle management and the expanding adoption of the 360 Encompass platform, along with AI-enabled autonomous coding, are expected to underpin long-term growth momentum.
Solid Q4 Results: Solventum exited the fourth quarter on a strong footing, with both earnings and sales surpassing expectations, driven by solid execution across MedSurg, Dental Solutions and Health Information Systems. Ongoing product innovation and improving commercial strategy — including greater specialization, clearer accountability and leadership changes — are accelerating decision-making and boosting conversion across key growth areas such as negative pressure wound therapy, antimicrobial IV site management and restorative dental products. The company also strengthened its MedSurg portfolio through the acquisition of Acera Surgical, marking its entry into regenerative tissue matrices and reinforcing tuck-in M&A as a core strategic lever for growth.
Downsides of SOLV Stock
Potential Raw Material Cost Step-Up From 3M Supply Agreement: Solventum disclosed that under its long-term supply agreement with 3M, the supplier holds a contractual option in 2027 to increase the cost of certain raw materials supplied. If this option is exercised, it could create a 100-basis-point margin headwind. The company emphasized that it is actively working with 3M to explore alternatives that could avoid this outcome. SOLV owns the intellectual property rights for these materials within its field of use, meaning it has the option to source the materials from other chemical manufacturers if necessary.
Trend in Estimate Revision
SOLV has been witnessing a stable estimate revision trend for 2026. In the past 30 days, the Zacks Consensus Estimate for its earnings per share (EPS) has remained stable at $6.44.
The Zacks Consensus Estimate for the company’s first-quarter revenues is pegged at $1.98 billion, implying a 4.2% decline from the year-ago quarter’s reported number.
Other Key Picks
Some other top-ranked stocks from the broader medical space are Pacific Biosciences of California (PACB - Free Report) , Phibro Animal Health (PAHC - Free Report) and Cardinal Health (CAH - Free Report) .
Pacific Biosciences of California, currently sporting a Zacks Rank #1 (Strong Buy), reported a fourth-quarter 2025 adjusted loss of 12 cents per share, which is 36.8% narrower than the Zacks Consensus Estimate. Revenues of $44.6 million beat the Zacks Consensus Estimate by 9.4%. You can see the complete list of today’s Zacks #1 Rank stocks here.
PACB has an estimated earnings recession rate of 1.9% compared with the industry’s 12.7% rise. The company’s earnings beat estimates in the trailing four quarters, the average surprise being 27.7%.
Phibro Animal Health, currently carrying a Zacks Rank #2, reported second-quarter fiscal 2026 adjusted EPS of 87 cents, which surpassed the Zacks Consensus Estimate by 27.1%. Revenues of $373.9 million beat the Zacks Consensus Estimate by 4.7%.
PAHC has an estimated long-term earnings growth rate of 21.5% compared with the industry’s 12.1% rise. The company’s earnings beat estimates in the trailing four quarters, the average surprise being 20.1%.
Cardinal Health, currently carrying a Zacks Rank #2, reported a second-quarter fiscal 2026 adjusted EPS of $2.63, which surpassed the Zacks Consensus Estimate by 10%. Revenues of $65.6 billion beat the Zacks Consensus Estimate by 0.9%.
CAH has an estimated long-term earnings growth rate of 15% compared with the industry’s 9.2% rise. The company’s earnings beat estimates in the trailing four quarters, the average surprise being 9.3%.
Zacks' 7 Best Strong Buy Stocks (New Research Report)
Valued at $99, click below to receive our just-released report
predicting the 7 stocks that will soar highest in the coming month.
View the Zacks #1 Rank List
Image: Bigstock
Here's Why You Should Add Solventum Stock to Your Portfolio Now
Key Takeaways
Solventum Corporation (SOLV - Free Report) is well-poised for growth in the coming quarters, driven by strong demand across its business segments, supported by continued investment in innovation, R&D and digital capabilities. The optimism, led by a solid fourth-quarter 2025 performance and a solid restructuring program, is expected to contribute further. However, concerns regarding a rise in raw material costs persist.
In the year-to-date period, this Zacks Rank #2 (Buy) company’s shares have lost 11.6% compared with the industry’s 8.9% decline and the S&P 500’s 4.3% rise.
The renowned global healthcare solutions provider has a market capitalization of $12.2 billion. The company projects 4.3% earnings growth for 2026 and expects to maintain its strong performance going forward. Solventum’s earnings surpassed the Zacks Consensus Estimate in each of the trailing four quarters, the average surprise being 12.4%.
Let’s delve deeper.
Image Source: Zacks Investment Research
Key Drivers of SOLV Stock
Future Cost Transformation Program: Solventum introduced its multi-year “Transform for the Future” restructuring program, targeting approximately $500 million in cost savings through operational efficiencies, system streamlining and automation, with benefits starting in 2026 and the majority realized from 2027 onward to support margin expansion and reinvestment. This builds on the successful completion of the Solventum Way program in 2025, which created a more flexible operating structure and delivered $125 million in annualized savings at a lower-than-expected cost, further strengthening the company’s ability to fund growth initiatives.
Strategic Growth Drivers: Solventum identified five core growth drivers that are expected to account for more than 80% of its future expansion, centered on segments where it already holds strong brand equity and clinical differentiation. Within MedSurg, negative pressure wound therapy continues to represent a sizable opportunity, fueled by growing adoption of Prevena and the V.A.C. Peel and Place dressing, while IV site management is gaining traction on the back of increasing demand for Tegaderm CHG and ample room for further market penetration.
The company is also seeing steady progress in sterilization assurance, supported by recent Attest product introductions. Beyond MedSurg, innovation remains a key pillar, with roughly 20 new product launches planned over the next two years. In Dental, growth is being driven by core restorative offerings such as Clinpro Clear and Filtek Easy Match, while in Health Information Systems, revenue cycle management and the expanding adoption of the 360 Encompass platform, along with AI-enabled autonomous coding, are expected to underpin long-term growth momentum.
Solid Q4 Results: Solventum exited the fourth quarter on a strong footing, with both earnings and sales surpassing expectations, driven by solid execution across MedSurg, Dental Solutions and Health Information Systems. Ongoing product innovation and improving commercial strategy — including greater specialization, clearer accountability and leadership changes — are accelerating decision-making and boosting conversion across key growth areas such as negative pressure wound therapy, antimicrobial IV site management and restorative dental products. The company also strengthened its MedSurg portfolio through the acquisition of Acera Surgical, marking its entry into regenerative tissue matrices and reinforcing tuck-in M&A as a core strategic lever for growth.
Downsides of SOLV Stock
Potential Raw Material Cost Step-Up From 3M Supply Agreement: Solventum disclosed that under its long-term supply agreement with 3M, the supplier holds a contractual option in 2027 to increase the cost of certain raw materials supplied. If this option is exercised, it could create a 100-basis-point margin headwind. The company emphasized that it is actively working with 3M to explore alternatives that could avoid this outcome. SOLV owns the intellectual property rights for these materials within its field of use, meaning it has the option to source the materials from other chemical manufacturers if necessary.
Trend in Estimate Revision
SOLV has been witnessing a stable estimate revision trend for 2026. In the past 30 days, the Zacks Consensus Estimate for its earnings per share (EPS) has remained stable at $6.44.
The Zacks Consensus Estimate for the company’s first-quarter revenues is pegged at $1.98 billion, implying a 4.2% decline from the year-ago quarter’s reported number.
Other Key Picks
Some other top-ranked stocks from the broader medical space are Pacific Biosciences of California (PACB - Free Report) , Phibro Animal Health (PAHC - Free Report) and Cardinal Health (CAH - Free Report) .
Pacific Biosciences of California, currently sporting a Zacks Rank #1 (Strong Buy), reported a fourth-quarter 2025 adjusted loss of 12 cents per share, which is 36.8% narrower than the Zacks Consensus Estimate. Revenues of $44.6 million beat the Zacks Consensus Estimate by 9.4%. You can see the complete list of today’s Zacks #1 Rank stocks here.
PACB has an estimated earnings recession rate of 1.9% compared with the industry’s 12.7% rise. The company’s earnings beat estimates in the trailing four quarters, the average surprise being 27.7%.
Phibro Animal Health, currently carrying a Zacks Rank #2, reported second-quarter fiscal 2026 adjusted EPS of 87 cents, which surpassed the Zacks Consensus Estimate by 27.1%. Revenues of $373.9 million beat the Zacks Consensus Estimate by 4.7%.
PAHC has an estimated long-term earnings growth rate of 21.5% compared with the industry’s 12.1% rise. The company’s earnings beat estimates in the trailing four quarters, the average surprise being 20.1%.
Cardinal Health, currently carrying a Zacks Rank #2, reported a second-quarter fiscal 2026 adjusted EPS of $2.63, which surpassed the Zacks Consensus Estimate by 10%. Revenues of $65.6 billion beat the Zacks Consensus Estimate by 0.9%.
CAH has an estimated long-term earnings growth rate of 15% compared with the industry’s 9.2% rise. The company’s earnings beat estimates in the trailing four quarters, the average surprise being 9.3%.